Both companies are based in Switzerland and sell globally.

The acquisition is supported by 65 Equity Partners, which becomes a ~40% shareholder alongside the Braglia family. The combination of HAS and Cerbios creates a leader in the CDMO industry, bringing extensive expertise and a broader range of services to meet the evolving needs of the global pharmaceutical industry. With the backing of 65 Equity Partners, the new Group is positioned for growth, driven by rising demand for complex therapies and innovation in drug development across key therapeutic areas. HAS and Cerbios will continue to be guided by strong corporate culture and family ownership values, with a commitment to Switzerland’s Ticino region. This operation represents a pivotal moment in its growth and reflects continuous investments in excellence and technological development.

“This is a transaction that has been planned for a long time to create an internationally important chemical-pharmaceutical hub in Ticino. With the differentiated pipelines and clients of both companies, we will reach new milestones together and further improve the quality of the services offered to our clients. This joint commitment not only strengthens our market position but also reflects the commitment of both companies to the innovation project. We are also bringing together a combined workforce of over 400 people who will be at the heart of this new company. We are deeply grateful for their contribution and dedication as we look to the future with confidence, continuing to grow and innovate together”, states Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis SA.

“We are proud to join HAS Healthcare Advanced Synthesis SA and to significantly contribute to the strength and growth of the new Group. HAS represents the ideal partner to help us accelerate our growth and expand our range of offerings and the value we provide to our clients", adds Christian Suà, CEO of Cerbios-Pharma SA.